

November 9, 2023

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
--	--

Dear Sir / Madam,

**Sub: Purchase of entire equity shares of a stepdown subsidiary of the Company to make it a direct subsidiary of the Company.**

The Board of Directors of the Company at its meeting held today, November 9, 2023, has approved the purchase of entire equity shares of Theranym Biologics Private Limited, a step-down wholly owned subsidiary of the Company, from Curateq Biologics Private Limited, also a wholly owned subsidiary of the Company, and make Theranym Biologics Private Limited a direct subsidiary of the Company.

Additional disclosures as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided in **Annexure**.

Please take the information on record.

Yours faithfully,  
**For AUROBINDO PHARMA LIMITED**

B. Adi Reddy  
Company Secretary

Enclosures: as above

**Annexure**

a	Name of the target entity, details in brief such as size, turnover etc.;	Theranyam Biologics Private Limited (Theranyam), a wholly owned step-down subsidiary of the Company. Purchase of entire shares of Theranyam from Curateq Biologics Private Limited (Curateq), a wholly owned subsidiary of the Company. Theranyam was incorporated on 22/09/2022 and not commenced any commercial activities. The paid-up share capital of Theranyam is Rs.10 lakhs divided into 1 lakh equity shares of Rs.10 each.
b	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	Theranyam being a wholly owned step-down subsidiary of the Company and Curateq, also a wholly owned subsidiary of the Company, the three are related parties as per Regulation 2 (zb) of SEBI (Listing at Obligations and Disclosure Requirements) Regulations, 2015. The transaction is being undertaken between the holding company and its wholly owned subsidiary and accordingly there is no impact on a consolidated basis. As per provisions of Section 188 of Companies Act, 2013 and Regulation 23(5)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, provisions relating to related party transactions are not applicable in respect of transactions between holding company and its wholly owned subsidiary. The transaction is done at arm's length.
c	Industry to which the entity being acquired belongs;	Manufacturing / marketing of pharmaceutical products.
d	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To make it a direct subsidiary of the Company.
e	Brief details of any governmental or regulatory approvals required for the acquisition;	No governmental or regulatory approvals required.
f	Indicative time period for completion of the acquisition;	By November 30, 2023.
g	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration
h	Cost of acquisition and/or the price at which the shares are acquired;	Rs. 10 lakhs
i	Percentage of shareholding / control acquired and / or number of shares acquired;	100%
j	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Theranyam is a wholly owned step-down subsidiary of the Company incorporated on September 22, 2022 for manufacturing and marketing pharmaceutical products. Theranyam is yet to commence operations.

**AUROBINDO PHARMA LIMITED**

(CIN : L24239TG1986PLC015190)

[www.aurobindo.com](http://www.aurobindo.com)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833

Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)